Get the Stockscreener App
10.81
1.73%
-0.19
Pre-market:
11.49
0.68
+6.29%
Upstream Bio Inc stock is traded at $10.81, with a volume of 311.89K.
It is down -1.73% in the last 24 hours and down -33.31% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
See More
Previous Close:
$11.00
Open:
$11.01
24h Volume:
311.89K
Relative Volume:
0.96
Market Cap:
$579.38M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-8.4144
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-3.57%
1M Performance:
-33.31%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.50
$11.26
1-Week Range:
$10.41
$12.06
52-Week Range:
$10.36
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
10.81 | 579.38M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio (NASDAQ:UPB) Trading Up 8.5%Here's Why - MarketBeat
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Upstream Bio (NASDAQ:UPB) Trading Down 3%Here's What Happened - MarketBeat
Upstream Bio (NASDAQ:UPB) Shares Up 5.7%Time to Buy? - MarketBeat
Should You Scoop Up This 'Strong Buy' Biotech Before December 23? - MSN
Amgen Inc (AMGN-Q) QuotePress Release - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowShould You Sell? - MarketBeat
Newly Public Biotech Startup Hires Life Sciences Veteran as GC - Law.com
Upstream Bio (NASDAQ:UPB) Shares Gap DownWhat's Next? - MarketBeat
Upstream Bio Appoints Allison Ambrose as General Counsel - citybiz
Upstream Bio (NASDAQ:UPB) Shares Down 5%Time to Sell? - MarketBeat
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation (UPB) - Seeking Alpha
Upstream Bio To Be Added To Russell 2000 - MENAFN.COM
Upstream Bio to be Added to Russell 2000 - Baystreet.ca
Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewswire
Upstream Bio to Join Russell 2000® Index, Gaining Access to $10.5T Benchmark-Linked Assets - StockTitan
Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry (NASDAQ:UPB) - Seeking Alpha
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Upstream Bioprocessing Market to Reach USD 82.10 Billion by 2032 from USD 22.79 Billion in 2023 | CAGR of 15.35% - GlobeNewswire
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Upstream Bio CEO to Present at Piper Sandler Healthcare Conference Dec 3 | UPB Stock News - StockTitan
Upstream Bioprocessing Industry Analysis and Forecast, - GlobeNewswire
Upstream Bio, Inc.’s (NASDAQ:UPB) Quiet Period Set To End on November 20th - Defense World
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th - MarketBeat
Brokers Set Expectations for Upstream Bio Q4 Earnings - MarketBeat
Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Scrip
William Blair Weighs in on Upstream Bio Q4 Earnings - Defense World
Upstream Bio Inc (UPB) Quarterly 10-Q Report - Quartz
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
FMR LLC Acquires New Stake in Upstream Bio Inc - GuruFocus.com
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Upstream Bio initiated with an Overweight at Piper Sandler - MSN
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MarketBeat
Here are Tuesday's biggest analyst calls: Apple, Microsoft, Palantir, Eli Lilly, Broadcom, Krispy Kreme, Live Nation & more - Head Topics
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
Upstream Bio initiated with an Overweight at JPMorgan - MSN
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):